Investing.com and Yahoo Finance LLC may earn commission or revenue on some items through the links below.
Investing.com— For years, Bausch Health Companies Inc (NYSE:BHC)has been a stock Wall Street loved to avoid. Weighed down by a heavy debt load and legacy overhangs, the pharmaceutical manufacturer traded deep in the market's penalty box. But in October, the stock has erupted—surging 55.50% in a single month and begging investors to take a look.
When surveying healthcare, investors typically default to steady dividend-paying pharmaceutical giants or speculative clinical biotech bets. Yet the most powerful market moves often occur when a deeply out-of-favor operator proves that an operational turnaround is genuinely taking hold.
The surge caught many by surprise, but InvestingPro's models identified the inflection point early, selecting Bausch Health across multiple ProPicks AI strategies. Ahead of the November 1st rebalance, the models track a curated group of healthcare compounders—including precision laboratory instrument suppliers, commercial medical technology leaders, and specialized clinical research providers quietly generating double-digit gains.
Position ahead of the November update: Explore the Healthcare Heroes strategy on InvestingPro
13 quarters of growth: Inside the operational rebound
Bausch Health's October rally is off the back of a compelling turnaround. Under CEO Thomas Appio, the company has quietly strung together 13 consecutive quarters of year-over-year revenue and adjusted EBITDA growth across its core business.
That momentum accelerated sharply in its latest financial results. For the second quarter, consolidated revenue reached $2.85 billion—up 13% year-over-year and beating analyst forecasts by 7.1%—while adjusted EBITDA jumped 28% to $1.075 billion. Adjusted earnings of $1.26 per share topped Wall Street consensus by 22.3%, prompting management to raise full-year 2026 guidance across revenue, EBITDA, and operational cash flow.
Growth is accelerating across several core divisions. The company's gastrointestinal business, Salix, saw revenue climb 21% year-over-year to $758 million, led by flagship therapy Xifaxan surging 26%. Meanwhile, its medical aesthetics unit, Solta Medical, grew 38% year-over-year, bolstered by its Shibo integration in China that established a $330 million annualized segment profit run rate.
Crucially, expanding margins are feeding directly into debt reduction. Excluding Bausch + Lomb, adjusted EBITDA margin reached a record 59%, while operating cash flow climbed 44% to $637 million for the quarter. That allowed management to pay down $434 million in net debt in a single quarter down to $13.7 billion, systematically rebuilding financial breathing room.
Is there more upside after a 55% run?
After a stock surges more than 50% in a matter of weeks, investors naturally wonder if the easy money has already been made. Yet despite its October run, Bausch Health continues to trade at a severe valuation discount compared to broader healthcare peers.
The stock trades at a forward price-to-earnings multiple of just 1.38x, while its enterprise value sits at 5.45 times EBITDA. With a five-year beta of just 0.37, the business trades virtually uncorrelated with broad market swings, moving instead on its own operational execution and cash flow generation.
InvestingPro's comprehensive valuation models benchmark Bausch Health's Fair Valueat $9.90 per share, pointing to an additional 55.8% upside from its recent trading price of $6.35. Wall Street sentiment is similarly constructive: analysts maintain a median price target of $7.50, with RBC Capital reiterating a $9.00 target following the company's guidance raise.
Risks remain on the balance sheet, where total debt stands at $20.8 billion and long-term patent expirations require navigation. However, with gross profit margins holding firm at 71.8% and cash flow expanding rapidly, the valuation provides a substantial cushion that speculative healthcare trades simply lack.
Investors can review the complete breakdown of therapeutic revenues, debt maturity schedules, and cash flow projections in the Bausch Health Pro Research Reporton InvestingPro.
Track Bausch Health's turnaround milestones and Fair Value upside: Access the complete BHC Pro Research Report on InvestingPro
Capitalizing on healthcare's compounding power
Bausch Health's 55% breakout reflects a broader trend that has made healthcare Wall Street's top-performing sector over the past six months. With interest rates elevated and tech valuations under fire, institutional capital is steadily rotating into recession-resistant cash flows.
A 100% win rate in ProPicks AI's Healthcare Heroes strategy shows the power of that rotation. Beyond Bausch Health, the strategy delivered double-digit gains across precision laboratory suppliers, clinical trial leaders, and global biotechs—averaging a 12.8% monthly return without taking on speculative tech risk.
On November 1st, ProPicks AI strategies—inlcuing by Healthcare Heroes , Mid-Cap Movers , and Top Value Stocks , among others—will refresh their selections to capture newly emerging market mispricings.
For investors seeking high-conviction ideas ahead of next month's market moves, full access costs just $9 a month.
Don't miss the November 1st rebalance: Unlock all top-rated ProPicks AI selections
Disclosure: The author holds no position in the stocks mentioned. Data and financial metrics as of October 30, 2026.
Original Article
Up 55% in October: Is Bausch Health's turnaround just getting started?
Top AdTech stocks to watch as third quarter earnings approach - B Riley
RBC Capital cuts Medical Properties Trust to Underperform on tenant risks
